A central neuronal mechanism underlying instability in epilepsy is disruption of the normal balance between excitation and inhibition. Under physiological conditions, neural circuits rely on tightly regulated interactions between excitatory and inhibitory neurons to support information processing while preventing uncontrolled synchronization. This balance is not static; it is continuously adjusted across synaptic, cellular, and network levels to permit flexible activity without loss of stability. Seizures emerge when this regulatory equilibrium is disturbed, and excitatory influences begin to outweigh the inhibitory restraints that normally confine neuronal firing in space and time [24, 32].

Excessive excitatory drive is one major route through which this imbalance develops. Glutamatergic transmission is essential for normal synaptic communication, plasticity, and circuit recruitment, but when glutamate release is excessive, postsynaptic responsiveness is enhanced, or excitatory synapses become pathologically strengthened, local activity can be amplified beyond physiological limits [32, 33]. Increased activation of excitatory pathways may facilitate recurrent firing, promote spread to neighboring neuronal populations, and lower the threshold for synchronized discharge. In epileptic networks, such changes can be reinforced by recurrent excitatory loops and activity-dependent synaptic strengthening, allowing transient bursts of excitation to evolve into more persistent and self-amplifying instability [33].

At the same time, reduced inhibition is an equally important determinant of excitatory dominance. Inhibitory interneurons normally constrain principal cell firing, regulate the temporal precision of network activity, and limit the spatial spread of excitation. Their function is therefore not restricted to suppressing discharge frequency; they also help organize oscillatory timing and prevent neuronal ensembles from entering hypersynchronous states [32, 34]. When inhibitory tone is weakened, circuits become less able to dampen activity bursts, restrict recruitment, or restore stable firing patterns after perturbation. This reduction in inhibition may arise through impaired interneuron function, decreased inhibitory drive, altered synaptic responsiveness, or broader changes in inhibitory network organization [34, 35]. Even in the absence of markedly elevated excitatory transmission, a relative failure of inhibition may be sufficient to destabilize the circuit.

Excitation–inhibition imbalance is also shaped by synaptic organization. Epileptic circuits often show altered excitatory coupling, impaired feedforward or feedback inhibition, and changes in synaptic strength that favor amplification over containment [33–35]. These changes do not simply increase neuronal activity in a general sense; they alter how activity is distributed across the circuit, how effectively it is restrained, and how easily it is propagated. Repeated seizures, developmental abnormalities, or prior injury may progressively remodel synaptic architecture in ways that shift signaling from adaptive responsiveness toward recurrent excitability. In this sense, synaptic imbalance is both a driver and a consequence of network instability [33, 35].

Altered firing thresholds further intensify this destabilized state. Neurons within epileptic circuits may become more responsive to synaptic input, more likely to fire repetitively, or more prone to burst discharge in response to stimuli that would not normally generate pathological output [34, 36]. Such changes increase the ease with which local neuronal populations are recruited into synchronized activity. Once thresholds for firing and recruitment are lowered, even modest perturbations may trigger disproportionate network responses, particularly when recurrent excitation is already enhanced and inhibitory containment is weakened [36, 37]. This helps explain why epileptic tissue may become highly sensitive to otherwise minor physiological or environmental fluctuations.

A key point is that excitation–inhibition imbalance should not be understood as a purely local cellular defect. Its pathological significance emerges at the network level, where excessive excitation, inadequate inhibitory restraint, altered synaptic organization, and lowered firing thresholds interact to promote coordinated discharge across interconnected neuronal populations [24, 34, 37]. The same degree of excitatory enhancement may have different consequences depending on circuit architecture, developmental stage, regional connectivity, and the integrity of surrounding regulatory systems. For this reason, excitation–inhibition imbalance is best viewed not simply as “too much excitation” or “too little inhibition”, but as a disturbance in the neuronal organization of circuit stability.

Within the broader framework of this review, excitation–inhibition imbalance represents a foundational neuronal driver of epileptic instability. It defines one of the principal routes by which circuits become vulnerable to recurrent discharge, but it does not by itself explain the full heterogeneity, persistence, or progression of epilepsy. Its functional consequences are shaped by extracellular buffering, glial regulation, inflammatory state, and circuit remodeling, which together determine whether neuronal instability remains limited or evolves into a chronic epileptic condition. The next subsection therefore examines one of the most important mechanistic dimensions of this imbalance in greater detail: GABAergic dysfunction.

Among the neuronal mechanisms that contribute to instability in epilepsy, GABAergic dysfunction is one of the most central and mechanistically informative. In the healthy brain, GABAergic signaling provides the principal inhibitory constraint on excitatory activity and is essential for limiting firing probability, shaping temporal precision, coordinating oscillatory behavior, and restricting the spread of excitation. Through these functions, inhibitory circuits do more than suppress neuronal output in a general sense; they actively organize when, where, and how neural ensembles can fire without entering pathological synchrony [38, 39]. Disruption of this inhibitory architecture is therefore a major route through which epileptic networks lose stability.

A common manifestation of GABAergic dysfunction in epilepsy is reduced inhibitory tone. When inhibitory transmission is weakened, neurons become more susceptible to recurrent firing, local activity is less effectively contained, and circuit synchronization becomes easier to initiate and sustain [38, 40, 41]. This reduction may result from interneuron loss, impaired interneuron recruitment, decreased GABA synthesis or release, altered postsynaptic responsiveness, or seizure-associated remodeling of inhibitory circuits [38, 39, 42]. Importantly, inhibitory control is not uniform across the brain. Distinct interneuron populations contribute differently to feedforward inhibition, feedback restraint, oscillatory timing, and spatial confinement of excitation, such that selective dysfunction of particular inhibitory microcircuits may produce different forms of epileptic instability [38, 39]. Thus, reduced inhibitory tone should not be understood simply as a quantitative decline in inhibition, but as a disturbance in the architecture of inhibitory control.

An additional layer of complexity arises from alterations in GABA receptor composition and function. GABAergic inhibition is mediated primarily through GABA_A and GABA_B receptors, which differ in localization, kinetics, and downstream signaling properties. Within the GABA_A receptor family, subtype composition influences channel behavior, pharmacological sensitivity, synaptic targeting, and the balance between rapid and persistent inhibitory signaling [26, 41, 43]. Changes in receptor expression, trafficking, clustering, or subunit composition can therefore alter inhibitory efficacy even when presynaptic GABA release is relatively preserved [42, 44, 45]. Such receptor-level alterations are especially relevant in epilepsy because they may reshape inhibitory strength, timing, and responsiveness in ways that are region-specific, stage-dependent, or linked to prior seizure activity. This subtype-level diversity is especially important because GABA-ρ receptors display distinctive molecular pharmacology and functional properties that can shape inhibitory signaling beyond the classical GABA_A/GABA_B framework [46]. Pharmacological studies of GABA-ρ2 receptors further support the idea that inhibitory receptor subtypes differ in ligand sensitivity and subtype selectivity, which may be relevant when considering receptor-level modulation of inhibitory tone [47].

A particularly important distinction in this context is that between phasic and tonic inhibition. Phasic inhibition is mediated largely by synaptic GABA release and generates temporally discrete inhibitory currents that constrain moment-to-moment firing. Tonic inhibition, by contrast, arises from persistent activation of extrasynaptic receptors and exerts a more sustained influence over baseline neuronal excitability [40, 48]. Both forms are essential, but they regulate network behavior in different ways. Phasic inhibition contributes strongly to temporal precision and rapid suppression of synaptic excitation, whereas tonic inhibition helps set the background excitability of neurons and their responsiveness to incoming input. Disturbances in either mode can destabilize circuits, but the consequences may differ depending on cell type, receptor distribution, developmental stage, and disease context [40, 48, 49]. In epilepsy, this distinction is important because inhibitory dysfunction may reflect not only an overall loss of inhibition, but also a selective distortion in how inhibitory control is distributed over time and across neuronal populations. At the molecular level, studies of GABA-ρ1 receptor ligand-binding residues show how specific binding-site features can influence ligand effects, reinforcing the broader point that inhibitory signaling depends not only on receptor presence but also on receptor subtype structure and pharmacological responsiveness [50].

Chloride homeostasis adds another critical determinant of GABAergic function. The inhibitory effect of GABA_A receptor activation depends on the transmembrane chloride gradient, which is maintained by chloride transport mechanisms and broader ionic homeostasis. When chloride regulation is disrupted, GABAergic currents may become less hyperpolarizing and therefore less effective at constraining excitability [51–53]. This has major implications for epilepsy, because inhibition may be functionally compromised even when GABA release and receptor activation remain present. Such changes can emerge during development, after repeated seizures, or under pathological conditions associated with injury and inflammation, thereby weakening one of the most important restraints on network excitation [52, 54, 55].

This altered chloride environment also helps explain the phenomenon of paradoxical GABA effects. Although GABA is classically inhibitory, its action is context dependent and may vary with developmental stage, chloride equilibrium, receptor distribution, and circuit state. Under certain conditions, GABAergic signaling may become depolarizing or may facilitate synchronization rather than suppress it [54, 56]. In epileptic tissue, this paradox may arise when disturbed chloride gradients reduce the inhibitory value of GABAergic input or when synchronized interneuron activity promotes coordinated discharge in already vulnerable networks. These observations do not challenge the central inhibitory role of GABA; rather, they show that GABAergic signaling must be interpreted within its ionic and circuit context. The presence of GABAergic activity does not automatically guarantee effective inhibitory control.

GABAergic dysfunction also contributes to instability through its effects on timing and network coordination. Inhibitory interneurons shape rhythmic activity, regulate ensemble timing, and determine how excitation is filtered across space and time. A network may therefore remain seizure-prone even when some inhibitory signaling is preserved if inhibitory control is mistimed, unevenly distributed, or unable to constrain recurrent excitation at critical moments [34, 38, 57]. This is an important point because it shifts the discussion away from inhibition as a purely quantitative variable and toward inhibition as an organizer of circuit stability.

Taken together, these findings show that GABAergic dysfunction in epilepsy extends far beyond a simple decrease in inhibition. Reduced inhibitory tone, receptor subtype alterations, disturbed relationships between tonic and phasic inhibition, chloride dysregulation, and paradoxical GABA effects all contribute to a more unstable neuronal environment [34, 51]. GABAergic signaling therefore provides one of the clearest mechanistic windows into how epileptic circuits lose the capacity to restrain excitability while still supporting highly organized pathological synchrony. At the same time, the consequences of GABAergic dysfunction are shaped by extracellular regulation, glial interactions, inflammatory state, and network remodeling, underscoring that inhibitory failure is a core neuronal driver of instability but not a self-sufficient explanation for the disease as a whole. The next subsection considers another major contributor to neuronal instability: alterations in ion channel function and intrinsic excitability.

Alterations in ion channel function and intrinsic excitability represent another major neuronal mechanism through which epileptic networks lose stability. Whereas excitation–inhibition imbalance and GABAergic dysfunction describe abnormalities in synaptic and circuit-level control, intrinsic excitability reflects how individual neurons respond to incoming input, initiate action potentials, sustain repetitive firing, and recover from activity. These properties depend on the coordinated behavior of ion channels that regulate sodium, potassium, and calcium flux across the membrane. When these channel systems are disrupted, neurons may become more easily depolarized, less effectively repolarized, and more likely to enter repetitive or burst firing states [58–60]. Such changes lower seizure threshold and increase the probability that local instability will be converted into synchronized network discharge.

Voltage-gated sodium channels are central to action potential initiation and propagation, and their dysregulation can markedly enhance neuronal excitability. Gain-of-function changes, impaired inactivation, abnormal channel expression, altered subcellular localization, or increases in persistent sodium current may all prolong depolarizing drive and facilitate repetitive firing [61–63]. In epileptic tissue, these changes can increase the responsiveness of neurons to synaptic input and promote more rapid recruitment of neighboring cells into coordinated discharge. Even modest alterations in sodium channel behavior may therefore have major effects when combined with weakened inhibition or recurrent excitatory circuitry [64, 65].

Potassium channels play an equally important stabilizing role by repolarizing the membrane, shaping firing frequency, generating afterhyperpolarization, and supporting spike-frequency adaptation. Mechanistic studies of KCNQ channel activation have shown that voltage sensor–pore coupling and phosphoinositide-related regulation are central to channel opening, illustrating how molecular regulation of potassium conductance can influence neuronal excitability [66]. When potassium channel function is reduced or improperly regulated, neurons may remain depolarized for longer periods, recover too quickly from prior firing, or lose the adaptive mechanisms that normally restrain repetitive discharge [60, 67]. Impaired repolarization and reduced afterhyperpolarization can make membrane behavior less stable and increase the likelihood of burst generation. Because potassium conductances help define whether excitation is self-limited or self-reinforcing, their dysfunction can strongly favor seizure initiation and persistence within vulnerable circuits [68, 69]. Among potassium-channel families, KCNQ/KV7 channels are particularly relevant because they regulate membrane excitability and have been explored as ligand-sensitive targets for reducing neuronal hyperexcitability [70].

Calcium channels introduce another important dimension of intrinsic instability. Calcium influx contributes to dendritic excitability, burst firing, neurotransmitter release, gene regulation, and activity-dependent plasticity, thereby linking immediate membrane behavior to longer-term cellular adaptation [71, 72]. Abnormal calcium channel function may increase excitability directly by enhancing burst propensity or indirectly by altering intracellular signaling pathways that reinforce pathological responsiveness [73, 74]. In epilepsy, this is particularly important because calcium-related changes do not only affect acute discharge patterns; they may also help stabilize hyperexcitable states over time. For this reason, calcium occupies a strategic position between intrinsic neuronal excitability and broader epileptogenic remodeling, a point that will be developed further in a later section.

These channel-level abnormalities converge at the level of membrane behavior. Neurons in epileptic circuits may exhibit lowered firing thresholds, increased input responsiveness, impaired spike-frequency adaptation, greater burst propensity, and reduced ability to maintain stable firing patterns during sustained stimulation [75–77]. Such membrane instability makes neuronal responses more easily amplified and more likely to shift from physiological signaling to pathological discharge. Importantly, intrinsic excitability is not simply a property of isolated neurons. Changes in membrane behavior influence how neurons participate in ensembles, how readily they are recruited into population activity, and how effectively they remain under inhibitory or modulatory control [78, 79]. In this way, intrinsic excitability links single-cell dysfunction to network-level instability.

Firing synchrony is a particularly important consequence of these changes. Seizures require not only heightened excitability, but also coordinated discharge across neuronal populations. Ion channel dysfunction can promote such coordination by increasing burst firing, lowering the threshold for collective recruitment, and favoring rapid propagation of depolarizing activity through vulnerable circuits [64, 75]. The pathological significance of altered intrinsic excitability therefore lies not merely in enhanced firing, but in its capacity to transform local membrane instability into synchronized network instability [64, 75, 78, 79]. This distinction is important because it explains why the effects of channel dysfunction depend on circuit context rather than on single-cell behavior alone.

At the same time, ion channel and intrinsic excitability changes should not be treated as a complete explanation for epilepsy. They provide compelling evidence that neuronal instability is real, biologically meaningful, and often sufficient to create a permissive substrate for seizure generation [64, 71]. Yet the marked heterogeneity of epilepsy indicates that abnormal channel function alone cannot fully explain why seizure susceptibility differs across brain regions, developmental stages, pathological settings, or individual patients. The effects of intrinsic neuronal instability are shaped by extracellular conditions, glial buffering, inflammatory signaling, and activity-dependent circuit remodeling, all of which influence whether hyperexcitable neurons remain contained or become part of a chronically unstable epileptic network [18, 80]. Ion channel dysfunction is therefore best understood as an essential neuronal component of epileptic instability, but one whose consequences are realized within a larger neural–glial system.

Together, excitation–inhibition imbalance, GABAergic dysfunction, and altered intrinsic excitability define a core set of neuronal mechanisms that promote epileptic instability. These mechanisms establish the central importance of neuronal pathology in seizure generation, but they also point toward a broader conclusion: neuronal dysfunction alone does not fully account for the emergence, persistence, and progression of epilepsy. That broader context becomes clearer in the next section, which examines the glial mechanisms that regulate, amplify, or constrain network instability in epileptic brain states.

Astrocytes are central regulators of the extracellular environment in which neuronal signaling occurs and therefore play a major role in determining whether neural networks remain stable or become seizure-prone. Although epilepsy has traditionally been interpreted through neuron-centered mechanisms, it is increasingly clear that astrocytes are not passive support cells or merely secondary responders to seizure activity. Rather, they actively shape the ionic, neurotransmitter, metabolic, and signaling conditions that influence neuronal excitability, synchronization, and recovery after perturbation [9, 14]. Within the framework of neural–glial network instability, astrocytic dysfunction is therefore highly consequential: if neurons generate the electrical output of the circuit, astrocytes help define the extracellular conditions under which that output remains constrained or becomes pathologically amplified.

One of the most important astrocytic functions in this context is potassium buffering. Neuronal activity releases potassium into the extracellular space, and astrocytes play a key role in clearing and redistributing this excess to maintain ionic homeostasis. Efficient potassium buffering helps prevent sustained depolarization of nearby neurons and limits the spread of hyperexcitability across local circuits [81, 82]. Astrocytic networks and spatial buffering mechanisms may further support redistribution of ionic loads across tissue domains, thereby helping to stabilize activity beyond the immediate site of potassium accumulation [14, 83]. When astrocytic potassium handling is impaired, extracellular potassium may accumulate, lowering the threshold for neuronal firing and favoring recurrent discharge. Even modest disruption of this buffering system can destabilize network behavior because potassium homeostasis is closely tied to membrane excitability, firing probability, and the capacity of tissue to recover after intense activity [82, 84]. In epileptic brain states, compromised astrocytic regulation of extracellular potassium may therefore transform transient increases in activity into more sustained and self-reinforcing instability.

A second major stabilizing function of astrocytes is glutamate uptake. Astrocytes normally remove glutamate from the extracellular space through high-affinity transport systems, thereby limiting excessive activation of excitatory receptors and preserving the temporal precision of synaptic transmission [85, 86]. This function is essential because glutamate is not only the principal excitatory neurotransmitter in the brain, but also a potent driver of pathological excitation when clearance mechanisms fail. Reduced astrocytic glutamate uptake can prolong excitatory signaling, increase extrasynaptic spillover, facilitate recruitment of neighboring neurons, and amplify the conditions that favor synchronized discharge [86, 87]. In this way, impaired glutamate handling does not merely intensify neuronal activity; it reshapes the excitatory landscape of the network and weakens one of the key extracellular restraints on seizure propagation.

Astrocytes also contribute importantly to water balance, another factor with direct implications for excitability. Water movement in the brain is closely linked to ionic homeostasis, extracellular volume, and tissue responses to intense neuronal activity. Through channels and membrane transport processes, astrocytes help regulate cellular swelling, extracellular space dynamics, and the movement of water associated with potassium and neurotransmitter clearance [88, 89]. Disturbances in astrocytic water regulation can promote astrocytic swelling and reduce extracellular space volume, thereby concentrating ions and neurotransmitters within a smaller compartment and favoring the conditions under which neuronal synchronization becomes easier to initiate and sustain [89, 90]. Although water balance is sometimes treated as a secondary physiological issue, in epilepsy it may directly alter the physical and ionic microenvironment in which hyperexcitability develops and spreads.

In addition to these homeostatic roles, astrocyte calcium signaling has emerged as an important mechanism through which astrocytes sense and respond to network activity. Astrocytes do not generate action potentials in the neuronal sense, but they exhibit dynamic intracellular calcium signals that reflect local stimulation and can influence neighboring cells and synapses [91–93]. These calcium-dependent responses allow astrocytes to integrate neuronal activity with extracellular regulation, vascular responses, and intercellular communication. In epileptic contexts, abnormal astrocytic calcium signaling may contribute to instability by altering local signaling loops, modulating synaptic function, or promoting conditions that reinforce excitability [94–96]. Astrocyte calcium activity is therefore important not only because it mirrors neuronal firing, but because it links astrocytes to the dynamic regulation of seizure-relevant microenvironments. At the same time, the mechanistic interpretation of astrocytic calcium signaling and its relationship to gliotransmission remains context dependent and is not resolved uniformly across experimental models and seizure settings.

Related to this is the role of gliotransmission, through which astrocytes can influence neuronal activity by releasing signaling molecules that affect synaptic and extrasynaptic function. Although the extent, mechanisms, and physiological relevance of gliotransmission remain actively debated, substantial experimental evidence supports the view that astrocytes can modulate circuit behavior through regulated release of neuroactive substances, including glutamate, ATP, D-serine, and related mediators [9, 92, 97]. In epilepsy, such signaling may become maladaptive if it enhances excitatory tone, alters synaptic responsiveness, or amplifies local synchronization. At the same time, astrocytic signaling may also reflect compensatory or context-dependent responses, suggesting that its effects cannot be interpreted as uniformly protective or pathological [27, 98]. This complexity is important because it underscores that astrocytes are active participants in network regulation, not merely cells that fail in housekeeping roles.

Taken together, these functions show that astrocytes regulate neuronal excitability through multiple, tightly interconnected mechanisms. Potassium buffering, glutamate uptake, water balance, calcium signaling, and gliotransmission are often discussed separately, but in practice they converge to shape the extracellular conditions that determine whether neuronal activity remains controlled or becomes unstable [11, 14]. A disturbance in one astrocytic domain may propagate into others: impaired potassium clearance can influence water movement, altered calcium signaling can affect gliotransmission, and deficient glutamate uptake can amplify depolarization and stress across the local network. Astrocytic dysfunction should therefore be understood not as an isolated support failure, but as a direct contributor to the extracellular permissiveness of epileptic circuits. This contribution is mediated through defined regulatory systems, including Kir4.1-dependent potassium handling, gap junction coupling, GLT-1/EAAT2-mediated glutamate uptake, aquaporin-4-associated water and volume regulation, and ATP–adenosine signaling.

Within the broader framework of this review, astrocytes are best understood as active regulators of seizure threshold and network resilience. Their dysfunction can lower the capacity of tissue to buffer excitation, recover from intense activity, and restrict the spread of pathological synchronization. This places astrocytes at the center of the neural–glial instability model developed here. They do not simply react to seizures after they occur; they help determine whether the extracellular environment favors containment, propagation, or persistence of epileptic activity [9, 27, 99]. The next subsection extends this glial perspective by examining microglia, which act as sensitive responders to tissue disturbance and important amplifiers of inflammatory and synaptic mechanisms of instability.

Microglia are highly responsive regulators of the brain microenvironment and are increasingly recognized as important contributors to epileptic instability. Traditionally viewed primarily as immune sentinels or secondary responders to injury, microglia are now understood to participate actively in the sensing, interpretation, and modulation of changes in neuronal activity and tissue state. In epilepsy, this is especially important because microglia occupy a strategic position at the interface of excitability, inflammation, synaptic remodeling, and cellular stress [28, 35, 100]. Rather than functioning only as downstream markers of seizure-related pathology, they can influence whether local disturbances are contained, amplified, or converted into more persistent forms of network instability.

A central feature of microglial biology in epilepsy is the diversity of their activation states. Microglia do not behave as a uniform cell population, nor do they shift simply between “resting” and “activated” forms. Instead, they adopt context-dependent states shaped by developmental stage, regional identity, local signals, injury history, and disease progression [101–103]. In epileptic tissue, these states may include surveillance-like, reactive, inflammatory, phagocytic, or remodeling-associated phenotypes, each with distinct implications for network behavior. This heterogeneity matters because the consequences of microglial activation depend not only on whether activation is present, but also on its timing, intensity, and functional direction. Accordingly, microglial actions in epilepsy may be protective, maladaptive, or mixed, depending on the stage of disease, the nature of the initiating insult, and the local tissue environment. Early or transient responses may help clear damaged elements, remove debris, and support restoration of local homeostasis, whereas persistent or maladaptive activation may reinforce inflammation, alter synaptic organization, and prolong seizure susceptibility [28, 100]. Microglial activation should therefore be understood as a dynamic component of network regulation rather than a generic sign of pathology.

One major route through which microglia influence epileptic circuits is cytokine release. Activated microglia can produce and respond to a broad array of cytokines, chemokines, and related mediators that directly affect neuronal and glial function [17, 100]. In epileptic settings, these signals may lower seizure threshold by modifying receptor activity, altering ion channel behavior, influencing neurotransmitter systems, and shifting the extracellular environment toward a more excitable state [17, 100]. Cytokine release can also strengthen communication between microglia and other cell types, including astrocytes and neurons, thereby extending the impact of local activation beyond the initial site of disturbance. In this way, cytokine signaling becomes one of the major mechanisms through which microglia translate tissue stress into changes in circuit behavior.

Microglia also regulate network behavior through synaptic pruning and remodeling. Under physiological conditions, they contribute to refinement of synaptic architecture by monitoring synaptic activity, removing weak or damaged elements, and participating in activity-dependent circuit maintenance. In epilepsy, however, these processes may become dysregulated, leading to maladaptive changes in connectivity and microcircuit organization [35, 104, 105]. Excessive or mistargeted pruning may weaken inhibitory control, distort excitatory–inhibitory balance, or favor patterns of connectivity that support recurrent excitation. Conversely, insufficient removal of dysfunctional synaptic elements may allow unstable circuit components to persist. Microglial effects on synapses are therefore important not simply because they alter structure, but because they influence which patterns of connectivity are preserved, weakened, or amplified during epileptogenesis and chronic disease [28, 35].

Beyond the release of individual mediators, microglia contribute to broader inflammatory signaling programs that shape the progression from acute disturbance to more persistent network dysfunction. They respond to danger-associated signals, disrupted homeostasis, cellular debris, and altered neuronal activity with signaling cascades that intersect with BBB dysfunction, oxidative stress, and metabolic disturbance [30, 106]. These pathways can prime tissue for exaggerated responses to subsequent insults, sustain inflammatory amplification after seizures, and promote conditions favorable to maladaptive plasticity [28, 106]. Importantly, this broader inflammatory signaling is not merely a consequence of seizures. In some settings, it may precede overt seizure activity and help create a biologically permissive state for epileptogenesis. This makes microglia especially relevant to the transition from transient disturbance to chronic network instability.

The influence of microglia on epileptic networks is also shaped by their interactions with neurons and astrocytes. Microglia are highly sensitive to neuronal stress signals, altered firing patterns, ATP release, and synaptic dysfunction, allowing them to detect changes in local circuit state at an early stage [12, 107]. Their responses can then feed back onto neurons through cytokines, trophic factors, receptor-modulating signals, and synapse-directed effects. At the same time, microglia interact closely with astrocytes, and this relationship may be especially important in epilepsy. Astrocytes can influence microglial activation through extracellular mediators and inflammatory cues, while microglia can affect astrocytic reactivity, glutamate handling, and broader homeostatic functions [12, 107, 108]. These reciprocal interactions mean that microglial effects cannot be understood in isolation; they are embedded within a wider neural–glial signaling network in which inflammatory and homeostatic processes continuously shape one another.

At the molecular level, these effects may involve IL-1β/IL-1R1 and TNF-α signaling, HMGB1–TLR4 danger signaling, P2X7 receptor activation, NLRP3 inflammasome pathways, complement-mediated synaptic remodeling, and chemokine or fractalkine-related neuron–microglia communication.

A key point is that microglia do not simply amplify disturbance indiscriminately. Their role is context dependent and temporally dynamic. In some phases or models, microglial responses may limit tissue damage, promote clearance, and support short-term recovery after acute insults [28, 100, 109]. In other settings, prolonged or dysregulated activation may intensify inflammatory signaling, promote maladaptive remodeling, and sustain seizure-prone network states. This duality is important because it reinforces a central theme of the present review: glial cells are not secondary epiphenomena of epilepsy, but active regulators of whether network perturbations are resolved or escalated.

Taken together, these observations position microglia as sensitive sensors of network disturbance and potent amplifiers of epileptic instability. Through context-dependent activation states, cytokine release, synaptic pruning and remodeling, broader inflammatory signaling, and reciprocal interactions with neurons and astrocytes, microglia help determine whether local insults remain limited or evolve into chronic circuit dysfunction [12, 35, 100]. Within the neural–glial instability framework, microglia are therefore best understood not as passive inflammatory bystanders, but as dynamic cellular intermediaries linking tissue stress to seizure susceptibility, epileptogenic remodeling, and disease persistence. The next subsection briefly considers oligodendrocytes and myelin-related contributions, which, although less often emphasized, add further depth to the glial architecture of epileptic network dysfunction.

The broad influence of astrocytes and microglia on epileptic networks is mediated through specific molecular pathways that directly regulate excitability, extracellular homeostasis, inflammatory amplification, and synaptic organization. These pathways are important because they move the discussion of glia beyond general support functions and show how neuron–glia communication can actively stabilize or destabilize seizure-prone circuits.

One major astrocytic regulatory pathway involves potassium buffering through inwardly rectifying potassium channels, particularly Kir4.1, together with astrocytic gap junction coupling. During intense neuronal activity, extracellular potassium accumulation promotes depolarization and increases the likelihood of recurrent firing [82, 110]. Astrocytic Kir4.1-mediated potassium uptake and redistribution through coupled astrocytic networks help restrain this process by limiting the spatial and temporal spread of potassium elevation. When Kir channel function or astrocytic coupling is impaired, potassium clearance becomes less efficient, membrane excitability rises, and local activity is more likely to propagate into hypersynchronous discharge. This mechanism illustrates how astrocytes regulate network stability through a defined ionic pathway rather than through nonspecific support.

A second key astrocytic pathway is glutamate clearance through excitatory amino acid transporters, especially GLT-1/EAAT2 and related transport systems. Astrocytic glutamate uptake limits excitatory spillover, prevents excessive activation of synaptic and extrasynaptic glutamate receptors, and helps preserve the temporal precision of excitatory signaling. Reduced GLT-1/EAAT2 function can prolong extracellular glutamate exposure, strengthen excitatory recruitment, and increase the probability that local excitation will become self-amplifying [85, 111, 112]. This pathway is particularly relevant to the neural–glial instability framework because it links astrocytic transporter biology directly to seizure threshold, excitatory spread, and impaired recovery after intense activity.

Astrocytic water and volume regulation provide another molecular route to instability. Aquaporin-4, often functionally coupled to potassium and ion-water movement, contributes to the regulation of extracellular volume and ionic microenvironments. Disturbance of aquaporin-dependent water handling can alter extracellular space, concentrate ions and neurotransmitters, and increase the probability of synchronized neuronal firing [113, 114]. In this way, astrocytic water channels do not simply regulate tissue hydration; they influence the physical and ionic conditions under which epileptic synchronization becomes more or less likely.

Neuron–astrocyte signaling is also shaped by purinergic and adenosinergic mechanisms. ATP released during intense neuronal activity, tissue stress, or glial activation can act on purinergic receptors expressed by neurons, astrocytes, and microglia, thereby linking network activity to glial responses and inflammatory signaling [115, 116]. Extracellular ATP can be converted to adenosine, which generally acts as an endogenous anticonvulsant modulator through suppression of excitatory transmission and stabilization of network activity. Disruption of ATP–adenosine balance may therefore shift purinergic signaling from a homeostatic response toward a pro-excitatory or pro-inflammatory loop. This pathway is important because it shows how activity-dependent neuron–glia communication can either restrain or amplify instability depending on timing, receptor context, and disease stage.

Microglial regulation of network stability is strongly mediated by inflammatory receptor pathways. IL-1β/IL-1R1 signaling, TNF-α signaling, HMGB1–TLR4 activation, P2X7 receptor signaling, and NLRP3 inflammasome activation can each influence seizure susceptibility by modifying neuronal excitability, synaptic transmission, glial reactivity, and cytokine amplification [110, 117, 118]. These pathways provide molecular mechanisms by which tissue stress and seizure activity can be translated into a lower seizure threshold and a more permissive inflammatory environment. Importantly, they also create feedback loops: seizures and cellular stress can activate danger and cytokine pathways, while those pathways can further increase excitability and glial activation.

Microglia also alter network stability through complement-mediated synaptic remodeling. Complement components such as C1q and C3 can tag synaptic elements for microglial interaction and elimination. In physiological contexts, complement-dependent pruning contributes to circuit refinement, but in epilepsy this process may become maladaptive if inhibitory synapses are preferentially weakened, excitatory–inhibitory balance is distorted, or unstable connectivity patterns are preserved [105, 119, 120]. Complement signaling therefore provides a specific mechanism through which microglia can reshape circuit architecture and influence long-term epileptogenic remodeling.

Taken together, these pathways show that neuron–glia communication in epilepsy operates through defined regulatory mechanisms rather than only broad homeostatic support. Astrocytic Kir4.1 and gap junction coupling regulate potassium dynamics; GLT-1/EAAT2 regulates extracellular glutamate; aquaporin-4 helps shape ionic and water microenvironments; purinergic and adenosinergic signaling links activity to glial and neuronal modulation; inflammatory receptor pathways such as IL-1β/IL-1R1, HMGB1–TLR4, P2X7, and NLRP3 regulate inflammatory amplification; and complement pathways contribute to synaptic remodeling. These molecular mechanisms provide concrete biological routes through which glial cells alter seizure threshold, network resilience, and epileptogenic progression.

Although oligodendrocytes are less frequently emphasized than astrocytes or microglia in discussions of epilepsy, their inclusion adds important depth to a network-based view of disease. Oligodendrocytes are best known for generating and maintaining myelin, but their functions extend beyond passive insulation. By supporting axonal conduction, metabolic stability, and the temporal coordination of distributed signaling, oligodendroglial lineage cells contribute to the integrity of neuronal communication across circuits [121–123]. This is highly relevant to epilepsy because seizure generation and propagation depend not only on whether neurons fire, but also on how abnormal activity travels, synchronizes, and is sustained across connected networks. In disorders where epileptic activity extends beyond a single focal population, oligodendrocyte and myelin-related changes may therefore be especially relevant to large-scale coordination and propagation dynamics [29, 123].

Myelin is a major determinant of conduction velocity and spike timing, both of which influence how neuronal ensembles are coordinated across space and time. Disruption of myelin integrity can alter signal propagation, impair temporal precision, and reshape synchrony within distributed circuits [122, 124]. In epilepsy, such effects may be important because changes in conduction properties can modify how excitatory activity spreads through vulnerable pathways and how effectively inhibitory and excitatory signals remain coordinated at the network level [29, 123]. Thus, oligodendrocyte and myelin dysfunction may influence seizure susceptibility not simply by compromising axonal structure, but by changing the timing architecture through which circuit activity is organized.

Oligodendrocytes also provide important metabolic support to axons, helping sustain conduction during repeated firing and maintaining long-range transmission under conditions of high energetic demand. Disturbances in this support relationship may render axons more vulnerable to activity-related stress, particularly in the setting of recurrent seizures or chronic hyperexcitability [121, 125, 126]. Although the evidence base here is less extensive than for astrocytes or microglia, this aspect is conceptually important because it links oligodendroglial function to the energetic burden of unstable circuits rather than to structural insulation alone. In this sense, oligodendrocytes may influence not only how signals travel, but also how well axonal pathways tolerate repeated pathological activity.

In addition, seizure activity has been investigated in relation to oligodendrocyte lineage cells, myelin organization, adaptive myelin plasticity, and broader white matter integrity [127, 128]. Recurrent seizures, inflammatory signaling, developmental abnormalities, or injury-related processes may alter oligodendrocyte maturation, myelin maintenance, or circuit-level connectivity. Evidence suggests that these relationships may be bidirectional in some experimental models, with seizure-driven changes in oligodendrogenesis and myelination contributing to network synchrony and epilepsy progression; however, such alterations were not detected in a GRIN2B-related neurodevelopmental disorder model, indicating that these effects are likely context- and model-dependent [29, 128].

At present, oligodendrocyte-related mechanisms in epilepsy remain less well defined than astrocytic and microglial contributions. Nevertheless, the available evidence supports their inclusion within a broader glial architecture of network instability. Their relevance lies not only in replacing more established mechanisms of excitability or inflammation, but in extending the model to encompass axonal support, white matter organization, conduction dynamics, and myelin-associated regulation of circuit synchrony [122, 123]. This broader view strengthens the central argument of the present review: glial cells are not merely secondary responders to epileptic activity, but active contributors to whether unstable activity remains constrained, becomes seizure-prone, or is efficiently propagated across connected networks.

Taken together, astrocytes, microglia, and oligodendroglial lineage cells represent complementary but interconnected regulators of epileptic network behavior. Astrocytes shape extracellular permissiveness, microglia interpret and amplify tissue disturbance, and oligodendrocytes influence conduction stability, axonal support, and propagation dynamics. Considering these glial populations together provides a more complete understanding of how epilepsy emerges from interacting cellular systems rather than from neuronal dysfunction alone. This glial regulation of excitability leads naturally to calcium dysregulation, which functions as a shared neuronal–glial signaling axis linking acute activity disturbances to broader cellular and network instability.

The contribution of calcium dysregulation to epileptic instability is unlikely to be uniform across epilepsy subtypes. Rather, calcium-related mechanisms may differ in source, timing, cellular localization, and relative importance depending on whether epilepsy is genetic or acquired, focal or generalized, developmental or adult-onset, and whether seizures arise from a discrete structural substrate or a more distributed network disorder [5, 71, 149]. This distinction is important because calcium should be understood as a cross-cutting instability mechanism rather than a single identical pathway operating in all epilepsies.

In genetic epilepsies, calcium dysregulation may be especially relevant when pathogenic variants affect calcium channels, calcium-coupled excitability, synaptic release machinery, or signaling pathways that regulate neuronal firing and network synchronization [132, 150]. In these settings, calcium-related dysfunction may be closer to the initiating mechanism of instability, particularly when altered channel gating, burst propensity, neurotransmitter release, or developmental circuit maturation directly shifts excitability. However, even in genetic epilepsies, calcium does not act in isolation. Its effects are shaped by inhibitory tone, synaptic architecture, developmental stage, and compensatory changes in glial and network regulation.

In acquired epilepsies, including post-traumatic, post-ischemic, infection-associated, tumor-associated, and status epilepticus-related epilepsies, calcium dysregulation may be more strongly linked to injury responses, excitotoxic stress, mitochondrial dysfunction, endoplasmic reticulum stress, neuroinflammation, BBB disruption, and maladaptive remodeling [96, 137, 151]. Here, calcium may not be the primary initiating abnormality, but it can serve as a major mediator through which acute injury or repeated seizures become translated into persistent cellular stress and epileptogenic reorganization. In this context, calcium overload may interact strongly with inflammatory amplification, glial activation, oxidative stress, and metabolic failure.

Differences may also exist between focal and generalized epilepsies. In focal epilepsies, calcium-related instability may be concentrated within a local epileptogenic zone, where lesion-associated gliosis, altered astrocytic calcium signaling, synaptic reorganization, mitochondrial stress, or local excitatory–inhibitory imbalance promotes recurrent discharge. In such cases, calcium dysregulation may interact with region-specific structural pathology and local neuron–glia microenvironments. In generalized epilepsies, calcium mechanisms may be more closely linked to distributed circuit dynamics, including thalamocortical oscillations, widespread excitability regulation, and synchronization across large-scale networks [96, 149, 152]. Thus, the same broad category of calcium dysregulation may operate through different circuit architectures in focal versus generalized seizure disorders.

Developmental epileptic encephalopathies and early-life epilepsies add another layer of complexity. During development, calcium signaling contributes to neuronal maturation, synapse formation, gene expression, and activity-dependent circuit refinement. Calcium dysregulation in these settings may therefore affect both acute excitability and long-term developmental circuit organization [132, 153]. By contrast, in many adult-onset acquired epilepsies, calcium-linked mechanisms may be more strongly associated with injury, metabolic stress, inflammatory signaling, and structural remodeling after the initiating insult.

These distinctions support a subtype-sensitive interpretation of the neural–glial instability framework. Calcium dysregulation is presented here as a convergent mechanism linking excitability, glial signaling, inflammation, mitochondrial stress, and remodeling, but its clinical meaning depends on the epilepsy context. In some patients, calcium-channel dysfunction or calcium-coupled excitability may be a dominant driver. In others, calcium overload may be a downstream mediator of repeated seizures, inflammation, or injury. In still others, astrocytic or microglial calcium signaling may contribute to altered neuron–glia communication and network permissiveness. Recognizing this heterogeneity increases the clinical applicability of the framework by suggesting that calcium-related interventions, biomarkers, and therapeutic priorities should be matched to epilepsy subtype, disease stage, and dominant instability architecture rather than applied as a uniform model across all epilepsies.

Taken together, calcium dysregulation provides one of the most integrative mechanistic frameworks for understanding epilepsy. It links neuronal excitability, neurotransmitter release, intracellular store signaling, astrocytic responses, inflammatory activation, mitochondrial stress, plasticity, and injury within a single multi-level system [18, 143]. This does not mean that calcium is the sole driver of epileptic instability, but rather that it functions as a key mediator through which diverse pathological processes converge and interact. Importantly, the relative contribution of calcium dysregulation should be interpreted in a subtype- and stage-sensitive manner, because calcium-related mechanisms may act as primary drivers in some genetic epilepsies, downstream mediators of injury and inflammation in acquired epilepsies, local amplifiers in focal epileptogenic tissue, or contributors to distributed oscillatory instability in generalized epilepsies. Within the broader argument of this review, calcium dysregulation stands out as a unifying mechanism that helps explain how disturbances at molecular, cellular, and network levels become coupled across time and cell type.

The neural–glial network instability framework proposed in this review is not intended to replace established neuroinflammatory, ionic, computational, or neuron-centered models of epilepsy. Rather, it offers a higher-order explanatory layer that organizes these models within a shared systems-level account of how seizure-prone states emerge and become stabilized over time. In this framework, epilepsy is not reduced to a single initiating mechanism. Instead, seizure susceptibility is understood as the outcome of interacting disturbances in neuronal excitability, extracellular ion and neurotransmitter homeostasis, glial regulation, inflammatory signaling, calcium-dependent stress pathways, and circuit remodeling. The novelty of the framework therefore lies less in proposing an entirely new molecular trigger than in clarifying how multiple established mechanisms converge to erode compensation and promote persistent network instability.

This distinction is especially important in relation to neuroinflammatory frameworks of epileptogenesis. Neuroinflammation is often described as a driver of seizure susceptibility and epileptogenic progression, particularly through cytokine signaling, danger-associated pathways, BBB dysfunction, immune–glial activation, and maladaptive synaptic or structural remodeling. The present framework accepts this central role but expands it by positioning inflammation not simply as an upstream pathological trigger or downstream consequence of seizures, but as one component of a broader feedback architecture. Inflammatory mediators can lower seizure threshold by altering receptor function, ion channel behavior, synaptic transmission, astrocytic homeostasis, and microglial remodeling. At the same time, seizures, calcium overload, metabolic stress, extracellular ionic disturbance, and tissue injury can further activate inflammatory pathways. Thus, inflammation is redefined here as an amplifier and stabilizer of network instability: it helps determine whether an acute disturbance is resolved, remains compensated, or becomes biologically consolidated into chronic epileptogenic vulnerability.

The framework also differs from computational and ionic models while remaining compatible with them. Computational and ionic models have shown that changes in extracellular and intracellular ion concentrations, especially K⁺ and Na⁺ dynamics, can support nonlinear state transitions, network bistability, seizure initiation, and seizure termination. The neural–glial instability framework does not dispute these mechanisms and does not claim that K⁺/Na⁺-dependent transitions are unnecessary. Instead, it places ionic bistability within the biological context that determines how such ionic conditions arise, persist, or recover. Astrocytic potassium buffering, sodium-dependent glutamate uptake, chloride homeostasis, energy metabolism, BBB integrity, inflammatory signaling, and seizure-induced remodeling all influence whether ionic disturbances remain transient or become part of a self-reinforcing epileptic state. In this sense, ionic models describe an important dynamical mechanism of seizure-state transition, whereas the neural–glial instability framework asks how cellular, glial, inflammatory, metabolic, and structural processes create or constrain the conditions under which those transitions become likely.

Therefore, the framework should be understood as a multi-scale integrative model rather than a competing single-mechanism hypothesis. Its contribution is to connect mechanistic explanations operating at different levels: ion concentration dynamics and bistability at the biophysical level; neuronal excitability and inhibition at the circuit level; astrocytic and microglial regulation at the cellular level; inflammatory and calcium-linked stress at the molecular signaling level; and remodeling at the chronic disease level. By linking these layers, the model helps explain why similar ionic or inflammatory perturbations may produce different outcomes depending on tissue context, developmental stage, disease etiology, glial state, metabolic reserve, and prior seizure history. This integrated view also provides a stronger basis for translational reasoning, because it suggests that durable seizure control may require not only suppressing acute hyperexcitability, but restoring the stabilizing mechanisms that prevent networks from entering or remaining in pathological seizure-prone states.

The translational contribution of the neural–glial instability framework is that it shifts clinical reasoning from seizure suppression alone toward identification of the dominant biological processes that make a given network seizure-prone. Traditional therapeutic logic has often prioritized reduction of excessive neuronal firing, enhancement of inhibition, or interruption of seizure propagation. These remain essential goals, but the present framework suggests that diagnosis and treatment may also benefit from asking why the network remains permissive for recurrent seizures in the first place. In this view, epilepsy may reflect different instability architectures across patients: some may be driven primarily by impaired inhibitory control, others by astrocytic failure of potassium or glutamate homeostasis, others by inflammatory amplification, calcium-linked intracellular stress, BBB dysfunction, maladaptive remodeling, or combinations of these mechanisms.

This perspective opens several translational avenues that are less apparent in models focused mainly on acute hyperexcitability. First, it supports mechanism-informed diagnostic profiling, in which electrophysiological, imaging-based, molecular, inflammatory, metabolic, and clinical features are interpreted together to identify the dominant instability pattern. Second, it supports dynamic monitoring of seizure risk, because a network may move from a partially compensated state toward a decompensated seizure-prone state before recurrent seizures become clinically obvious. Third, it provides a rationale for mechanism-guided treatment selection, where therapies are matched not only to seizure type but also to the biological drivers of instability. For example, a patient with evidence of inflammatory amplification or BBB disruption may require a different adjunctive strategy than a patient whose instability is dominated by ion channel dysfunction, impaired inhibition, or structural network reorganization.

The framework also has implications for disease modification. If epileptogenesis reflects a progressive loss of network compensation, then treatment opportunities may exist before instability becomes structurally embedded. Interventions aimed at preserving astrocytic homeostasis, limiting inflammatory feedback, reducing calcium-linked stress, stabilizing the BBB, or preventing maladaptive circuit remodeling may be most valuable during vulnerable transition periods after status epilepticus, traumatic brain injury, infection, developmental disruption, or other epileptogenic insults. In this sense, the framework does not simply add new therapeutic targets; it reorganizes existing targets according to when and why they may matter during disease evolution.

Finally, this approach supports combination and precision strategies. Because chronic epilepsy often reflects interacting mechanisms rather than a single isolated abnormality, durable stabilization may require coordinated treatment across multiple levels: acute seizure suppression, restoration of inhibitory balance, glial and inflammatory modulation, metabolic or calcium-stress control, neuromodulation, and circuit-directed intervention when appropriate. The clinical value of the neural–glial instability framework therefore lies in providing a structured way to connect mechanistic biology with patient stratification, biomarker development, and rational therapeutic selection, including distinction between patients whose instability is dominated by impaired glial homeostasis, inflammatory amplification, ionic or inhibitory dysfunction, calcium-linked stress, structural remodeling, or mixed mechanisms.

A central translational implication of the neural–glial instability framework is that the transition from compensated network function to decompensated seizure susceptibility may be empirically trackable. Compensation refers to a state in which neural and glial regulatory mechanisms are stressed but still able to preserve sufficient inhibitory restraint, extracellular homeostasis, metabolic support, inflammatory control, and recovery capacity. Decompensation occurs when these stabilizing mechanisms are no longer able to contain perturbations, allowing lower seizure thresholds, increased hypersynchrony, impaired recovery, and progressive epileptogenic remodeling [216–218]. Although no single biomarker is likely to define this transition across all epilepsy syndromes, several dynamic features may help mark movement toward decompensation.

Electrophysiological measures are among the most clinically accessible candidates. A rising burden of interictal epileptiform discharges, increased high-frequency oscillations, abnormal phase–amplitude coupling, increased pathological synchrony, reduced network flexibility, altered functional connectivity, and impaired recovery of background activity after seizures may all indicate declining network resilience [219–221]. EEG and MEG may therefore be useful not only for detecting epileptic activity, but also for estimating whether a network is becoming less able to return to a stable baseline after perturbation. In this context, the most informative measures may be longitudinal and dynamic rather than static: increasing discharge burden, shortening inter-seizure intervals, seizure clustering, or worsening sensitivity to sleep disruption, stress, fever, or metabolic challenge may suggest that compensatory capacity is being progressively eroded.

Metabolic and imaging markers may provide a second layer of information. A transition toward decompensation may be associated with altered glucose utilization, lactate accumulation, mitochondrial stress, impaired perfusion–metabolism coupling, or imaging evidence of regional hypometabolism or hypermetabolism depending on disease stage and epilepsy subtype. Structural and functional MRI, PET, diffusion imaging, and other imaging approaches may also help identify gliosis, BBB disruption, white matter abnormalities, altered network connectivity, or progressive circuit reorganization [218, 222]. These markers are especially relevant because they may capture the tissue-level consequences of impaired homeostatic recovery and the emergence of a more permissive epileptogenic environment.

Molecular and fluid biomarkers may further help identify the biological direction of instability. Candidate markers include inflammatory cytokines and chemokines, danger-associated signals such as HMGB1-related pathways, BBB-associated proteins, astrocytic markers such as GFAP or S100B, microglial or complement-related signatures, extracellular vesicle cargo, oxidative stress markers, and indicators of neuronal or glial injury [223–225]. Such markers should not be interpreted as epilepsy-specific in isolation. Their value would likely be greatest when combined with electrophysiological, imaging, clinical, and genetic information to identify whether decompensation is dominated by inflammatory amplification, glial homeostatic failure, metabolic stress, structural remodeling, or primarily neuronal excitability mechanisms.

From a clinical perspective, the compensation-to-decompensation transition is therefore best understood as a multimodal and dynamic process rather than a single threshold event. A patient may show partial compensation despite an underlying epileptogenic insult if EEG abnormalities are limited, metabolic reserve is preserved, inflammatory signaling is transient, and recovery after perturbation remains efficient. By contrast, convergence of increasing epileptiform activity, impaired postictal recovery, progressive imaging abnormalities, inflammatory or glial biomarker elevation, and worsening seizure clustering may indicate movement toward a decompensated state. This approach could help bridge mechanistic biology with clinical prediction by identifying patients who are not only experiencing seizures, but whose neural–glial systems are losing resilience over time.

Clinical translation of the neural–glial instability framework will require stratifying patients according to the dominant biological mechanisms sustaining network instability. This is especially important because glial dysfunction and inflammatory amplification may overlap but are not identical. Glial dysfunction refers primarily to failure of astrocytic or other glial homeostatic functions, including impaired potassium buffering, reduced glutamate uptake, altered water and volume regulation, abnormal astrocytic calcium signaling, disrupted metabolic support, or impaired neuron–glia communication. Inflammatory amplification refers more specifically to sustained or excessive immune–glial signaling, including cytokine release, danger-associated signaling, microglial activation, BBB disruption, complement-related remodeling, and persistent inflammatory feedback loops that lower seizure threshold and promote epileptogenic progression [118, 222, 224].

In a clinical or translational setting, patients with a predominantly glial-homeostatic instability pattern may be suggested by convergent evidence of astrocytic dysfunction, impaired extracellular regulation, and local network permissiveness without necessarily showing a strong systemic or tissue inflammatory signature. Candidate indicators may include increased astrocytic injury or reactivity markers such as GFAP or S100B, imaging evidence of gliosis or regionally altered astrocyte-associated pathology, abnormalities in extracellular potassium or glutamate handling where measurable in experimental or surgical settings, impaired postictal recovery, local metabolic stress, and seizure patterns consistent with focal extracellular permissiveness [96, 223]. These features would suggest that the epileptic network is unstable because homeostatic buffering and recovery mechanisms are insufficient.

By contrast, patients with a predominantly inflammatory-amplification pattern may show evidence of sustained cytokine, chemokine, danger, complement, or BBB-related signaling. Candidate indicators may include elevated inflammatory cytokines or chemokines, HMGB1-related danger signaling, IL-1β/TNF-related pathway activation, complement-related signatures, microglial activation markers, BBB-associated markers, or imaging evidence consistent with neuroinflammatory activity or barrier disruption [226, 227]. Clinically, this pattern may be especially relevant after status epilepticus, traumatic brain injury, infection, autoimmune or inflammatory insults, tumor-associated epilepsy, or other contexts in which immune–glial signaling may remain active beyond the initiating event.

A biomarker-driven stratification approach should not rely on any single marker in isolation. GFAP or S100B elevation, for example, may indicate astrocytic injury or reactivity but does not by itself prove that astrocytic homeostatic failure is the dominant driver of seizures. Similarly, cytokine elevation may indicate inflammatory activity but does not alone establish that inflammation is the primary cause of network instability [228, 229]. The most clinically useful strategy is likely to be multimodal: combining seizure semiology, epilepsy subtype, EEG/MEG dynamics, MRI/PET findings, BBB markers, inflammatory and glial fluid biomarkers, genetic information, treatment response, and longitudinal disease trajectory. Stratification should therefore be based on convergent patterns rather than single biomarkers.

This distinction has therapeutic implications. A patient whose instability profile is dominated by impaired glial homeostasis may benefit most from strategies aimed at restoring extracellular buffering, glutamate handling, astrocytic metabolic support, or local circuit recovery, alongside conventional antiseizure therapy. By contrast, a patient with prominent inflammatory amplification or BBB disruption may be a stronger candidate for adjunctive approaches targeting inflammatory signaling, immune–glial activation, barrier stabilization, or post-injury epileptogenic cascades. Patients with mixed profiles may require combination strategies that address both acute excitability and the broader glial–inflammatory environment that sustains seizure susceptibility.

Biomarker-driven stratification should therefore be understood as a way to move from syndrome-level classification toward mechanism-informed precision medicine. Rather than asking only whether a patient has focal or generalized epilepsy, temporal lobe epilepsy, post-traumatic epilepsy, or drug-resistant epilepsy, the neural–glial instability framework encourages an additional question: which stabilizing system has failed most prominently in this patient, and which biomarkers support that interpretation? This approach could improve patient selection for glial-targeted, anti-inflammatory, metabolic, neuromodulatory, or circuit-directed interventions and may help explain why patients with similar seizure classifications can differ substantially in treatment response.

Restoring inhibitory balance remains one of the most established and clinically important therapeutic strategies in epilepsy. Because excessive synchronization and recurrent excitation often emerge in the setting of weakened inhibitory restraint, enhancing inhibitory signaling has long been a central principle of antiseizure treatment [41, 230]. This logic is strongly supported by the mechanistic discussion in earlier sections: when GABAergic tone is reduced, receptor function is altered, chloride homeostasis is disrupted, or interneuron recruitment becomes less effective, networks become more vulnerable to uncontrolled excitation and seizure propagation [54, 231]. Therapeutic efforts aimed at reinforcing inhibition therefore remain highly relevant within the neural–glial instability framework.

Many current antiseizure medications act, directly or indirectly, by strengthening GABAergic inhibition. These approaches may enhance receptor activity, prolong inhibitory currents, increase GABA availability, or reduce the relative dominance of excitatory signaling, including through receptor-modulating agents, drugs that increase synaptic GABA tone, or therapies used for rapid seizure suppression in acute settings [41, 230]. Clinically, such strategies can be highly effective in suppressing seizures acutely and remain indispensable in both chronic epilepsy management and emergency seizure control. Their success reinforces a central principle: seizure activity often depends on insufficient inhibitory containment, and restoring that containment can provide meaningful clinical benefit.

At the same time, the limitations of GABAergic approaches are equally instructive. Not all patients respond adequately to treatments that enhance inhibition, and in some epileptic settings the underlying inhibitory deficit is not simply one of reduced GABA availability. Receptor subtype alterations, changes in tonic versus phasic inhibition, chloride dysregulation, interneuron network disruption, and context-dependent paradoxical GABA effects may all reduce the effectiveness of standard inhibitory therapies [41, 54, 231]. In such cases, strengthening GABAergic signaling pharmacologically may not fully restore stable inhibitory control because the broader circuit architecture and cellular context remain altered. This helps explain why seizure suppression and true network stabilization are not always equivalent.

A further practical limitation is that therapies that broadly enhance inhibition may also be constrained by sedation, cognitive adverse effects, tolerance in some settings, or incomplete long-term efficacy [41, 232]. These realities do not diminish the importance of GABAergic treatment, but they underscore that inhibitory enhancement alone may not provide durable control in all patients, particularly when epilepsy is maintained by mechanisms extending beyond acute excitability. In this sense, the clinical limits of inhibitory therapy reinforce the broader mechanistic argument of the present review.

A particularly important issue is that inhibitory therapies are often most effective at controlling acute excitability, whereas chronic epilepsy may also involve persistent glial dysfunction, calcium-dependent stress, inflammatory amplification, and structural circuit remodeling that lie outside a purely GABAergic solution [54, 230, 231]. If the extracellular environment remains permissive, if inflammatory signals continue to lower seizure threshold, or if recurrent excitatory pathways have become structurally embedded, then enhancing inhibition alone may provide incomplete or temporary benefit. This does not reduce the value of inhibitory therapies; rather, it clarifies why they are necessary but not always sufficient within a broader disease process.

These limitations also point toward more refined strategies for restoring inhibitory balance. Rather than viewing inhibition as a single global variable, future therapeutic approaches may need to consider which inhibitory mechanisms are disrupted, in which circuits, and at what stage of disease. Interventions that better address tonic versus phasic inhibition, chloride regulation, interneuron preservation or recruitment, and circuit-specific inhibitory architecture may prove more effective than uniformly increasing GABAergic tone. Such strategies would align more closely with the idea that epilepsy is a systems disorder in which inhibitory failure is biologically heterogeneous rather than mechanistically identical across patients and syndromes.

Within the therapeutic logic of this review, restoring inhibitory balance remains a foundational strategy, but one that must be understood within a broader neural–glial context. GABAergic approaches can reduce seizure expression and remain indispensable in clinical practice, yet their limitations highlight the need for multi-level therapies aimed at restoring stable network conditions rather than suppressing neuronal firing alone [41, 167, 231]. Restoring inhibition is therefore essential, but durable seizure control may also require correction of the extracellular, inflammatory, and circuit-level disturbances that undermine inhibitory stability in the first place.

If epilepsy is sustained in part by failures of extracellular regulation, inflammatory amplification, and maladaptive neural–glial signaling, then glial dysfunction becomes an important therapeutic target rather than a secondary consequence of neuronal disease. This is one of the central translational implications of the present review. Astrocytes and microglia actively shape seizure threshold, tissue recovery, inflammatory tone, and the long-term permissiveness of epileptic networks [14, 215, 233]. Therapeutic strategies that modulate glial dysfunction therefore have the potential not only to reduce seizure expression, but also to alter the conditions that allow instability to persist.

For astrocytes, one therapeutic objective is the restoration of homeostatic support functions that normally restrain excitability. Strategies that improve potassium buffering, enhance glutamate uptake, stabilize water regulation, support metabolic coupling, or reduce maladaptive astrocyte reactivity may be especially relevant in epileptic tissue where astrocytic dysfunction contributes to a permissive environment for hyperexcitability [14, 234, 235]. In principle, such approaches could reduce seizure susceptibility by strengthening the extracellular constraints that normally prevent excessive synchronization. This therapeutic logic is attractive because it targets network permissiveness rather than neuronal firing alone. At the same time, astrocytes are multifunctional cells whose effects depend on region, timing, and disease stage. An intervention that improves one astrocytic domain may alter others in unintended ways. Therapeutic approaches aimed at restoring astrocytic stability must therefore distinguish between protective homeostatic functions and context-dependent reactive states rather than treating astrocyte activity as uniformly pathological [14, 202, 235].

For microglia, the therapeutic goal is often different. Because microglia can amplify inflammatory signaling, reshape synaptic organization, and help sustain seizure-prone tissue states, strategies that reduce maladaptive microglial activation or shift microglial responses toward more protective programs may hold substantial translational value [28, 105, 233]. This does not imply that broad microglial suppression is always desirable. As discussed earlier, microglia can also support debris clearance, containment of injury, and short-term tissue recovery. The challenge is therefore not simply to inhibit microglia, but to modulate the timing, intensity, and direction of their responses. Therapies that blunt persistent inflammatory amplification while preserving protective surveillance or repair functions may be more effective than approaches based on indiscriminate immune suppression [106, 236].

A major strength of glia-directed therapy is that it may address mechanisms that conventional antiseizure medications leave relatively untouched. If recurrent seizures are reinforced by impaired astrocytic buffering, persistent microglial activation, glia-driven inflammatory signaling, or altered neural–glial communication, then neuron-centered treatments alone may provide incomplete stabilization [12, 14, 215]. In this sense, glial targeting could complement rather than replace established antiseizure therapy. Such combination logic may be especially important in chronic or drug-resistant epilepsy, where the network remains unstable despite ongoing efforts to suppress neuronal discharge.

At the same time, glia-directed interventions face substantial challenges. Glial states are heterogeneous, region-specific, temporally dynamic, and deeply integrated with normal brain function [12, 215, 235]. Astrocytes and microglia can be protective or maladaptive depending on disease stage, tissue context, and the nature of the underlying insult. This means that therapeutically relevant modulation will likely require more precise approaches than broad glial inhibition. Biomarker-guided targeting, cell-state-specific strategies, and better alignment between experimental models and patient biology may therefore be essential for translating glial therapeutics into clinically meaningful interventions.

Within the broader framework of this review, modulating glial dysfunction represents an effort to restore the extracellular and inflammatory architecture of network stability. This is clinically important because seizure persistence may depend not only on abnormal neuronal firing, but also on whether astrocytes and microglia continue to sustain a biologically permissive state for excitability, synchronization, and maladaptive remodeling. Glial therapies are therefore best understood as strategies to restore the extracellular and inflammatory conditions under which stable circuit function becomes possible, rather than as simple adjuncts to neuronal suppression.

Because calcium dysregulation links excitability, glial activation, mitochondrial dysfunction, inflammatory signaling, and chronic remodeling, it represents an especially attractive therapeutic target within a neural–glial instability framework. Interventions directed at calcium handling and intracellular stress pathways may have value not only because they reduce acute excitability, but because they may interrupt the molecular processes through which seizures become biologically embedded in cells and circuits [129, 237, 238]. In this sense, targeting calcium-related mechanisms offers a strategy that lies between symptomatic seizure suppression and deeper disease modification.

One therapeutic avenue involves limiting neuronal calcium overload. Excessive calcium entry during hyperexcitable states can reinforce burst firing, amplify neurotransmitter release, activate stress pathways, and increase vulnerability to injury [18, 129, 237]. Strategies that reduce pathologic calcium influx or improve calcium buffering may therefore help protect neurons from the feedforward consequences of repeated seizure activity. This logic is particularly important in chronic epilepsy, where recurrent episodes of calcium overload may contribute to persistent dysfunction even if each individual seizure is transient. Such approaches may therefore be relevant not only for reducing excitability, but also for slowing disease-promoting cellular consequences of repeated seizure burden.

A second therapeutic direction concerns intracellular calcium stores and endoplasmic reticulum stress-related signaling. Because calcium release from intracellular stores can amplify excitability and couple seizure activity to deeper forms of cellular stress, interventions that stabilize these pathways may reduce both acute network instability and longer-term cellular damage [136, 151]. This includes mechanisms associated with endoplasmic reticulum calcium release, store-related dysregulation, calcium-dependent coupling to endoplasmic reticulum stress pathways, and downstream signaling cascades that influence survival, plasticity, and inflammatory responsiveness [129, 135, 151]. Such approaches are appealing because they address intracellular consequences of epilepsy that are not fully captured by membrane-focused antiseizure therapies.

Calcium-targeted strategies may also be relevant to astrocytic and microglial signaling. Abnormal glial calcium dynamics can contribute to altered gliotransmission, inflammatory amplification, and persistent extracellular permissiveness for excitability [96, 143]. Therapeutic efforts that normalize calcium-dependent glial responses may therefore reduce maladaptive feedback loops linking seizures, glial activation, and chronic instability. As with glia-directed therapy more broadly, however, the challenge lies in distinguishing physiological calcium signaling from pathological amplification. Calcium is fundamental to normal brain function, so interventions must be sufficiently selective to avoid broad disruption of essential signaling processes [129, 143, 239].

Closely related to calcium dysregulation is the problem of intracellular stress, particularly mitochondrial dysfunction, oxidative stress, and maladaptive stress signaling. Repeated seizures impose heavy metabolic and ionic demands on neurons and glia, and when intracellular buffering systems are overwhelmed, cells may enter states that favor further instability rather than recovery [238, 240]. Therapies that support mitochondrial resilience, reduce oxidative burden, or interrupt stress-amplifying intracellular cascades may therefore help preserve network stability even if they do not act as classic antiseizure drugs [135, 237]. This expands the therapeutic horizon from controlling discharge to protecting the cellular systems that determine whether tissue remains recoverable or becomes chronically destabilized.

The translational promise of calcium- and stress-directed strategies lies in their ability to intervene at a mechanistic crossroads. Rather than targeting only the electrical expression of seizures, these approaches aim to weaken the intracellular pathways that connect acute hyperactivity to inflammation, injury, and remodeling [135, 215]. Within the framework of this review, they are therefore particularly important as potential disease-modifying strategies rather than as tools for seizure termination alone [230, 237]. Their ultimate value may depend on how well they can be integrated with approaches that restore inhibition, modulate glial dysfunction, and address circuit-level reorganization, rather than operating in isolation.

Limiting inflammatory amplification is another important therapeutic strategy within a neural–glial instability framework. Neuroinflammation can lower seizure threshold, reinforce glial dysfunction, disrupt tissue homeostasis, and promote epileptogenic remodeling. This approach is clinically relevant not simply because inflammation accompanies many epileptic conditions, but because persistent inflammatory signaling may help convert transient disturbances into chronic seizure-prone states [241]. Therapeutic efforts aimed at reducing inflammatory amplification therefore seek to interrupt the feedback loops through which seizures, glial activation, danger signaling, BBB dysfunction, and tissue stress reinforce one another over time [242].

One major rationale for anti-inflammatory intervention is the bidirectional relationship between seizures and inflammatory signaling. Seizures can activate cytokine pathways, innate immune signaling, danger-associated responses, and glial inflammatory programs, while these same pathways can feed back onto the network by altering excitability, synaptic regulation, and tissue recovery [243]. When such feedback becomes persistent, the brain may remain in a biologically sensitized condition even between overt seizures. From a therapeutic perspective, this means that reducing inflammatory tone may do more than attenuate associated pathology; it may directly reduce the permissiveness of epileptic tissue.

At the same time, inflammatory targeting in epilepsy is unlikely to succeed through broad suppression alone. Inflammatory responses are heterogeneous, temporally dynamic, and in some contexts partially protective. Acute inflammatory signaling may contribute to tissue containment or repair, whereas sustained or maladaptive activation may promote chronic instability. The challenge is therefore to distinguish inflammatory responses that should be restrained from those that should be preserved. Therapies aimed at specific cytokine pathways, modulation of innate immune signaling, BBB-stabilizing strategies, or targeted control of glial inflammatory states may therefore be more effective than indiscriminate immunosuppression [243].

This therapeutic logic also has important implications for epileptogenic transition. If inflammatory amplification contributes to the progression from acute insult to chronic epilepsy, then timely intervention may have disease-modifying potential rather than merely symptomatic value [241]. This is especially relevant in conditions such as status epilepticus, traumatic brain injury, infection-related epilepsy, or other inflammatory-prone epileptic states in which the tissue may enter a prolonged window of biological vulnerability [242]. In such contexts, limiting inflammatory amplification could help preserve network recoverability and reduce the likelihood that maladaptive remodeling becomes entrenched.

However, substantial translational challenges remain. The inflammatory biology of epilepsy varies by syndrome, timing, anatomical region, age, underlying etiology, and disease stage. Not all patients exhibit the same inflammatory profile, and not all inflammatory pathways are equally actionable. This makes biomarker-guided stratification especially important if anti-inflammatory therapies are to be used intelligently rather than empirically. Within the framework of this review, inflammatory targeting is therefore best viewed as part of a broader systems strategy: the goal is not simply to reduce immune activity, but to prevent inflammatory signaling from converting reversible instability into self-reinforcing chronic epilepsy.

The broader therapeutic message of this review is that effective epilepsy treatment may require restoring network stability, not simply suppressing neuronal firing acutely. This makes network-level and precision approaches especially important, because they are designed to act on the organization, dynamics, and patient-specific architecture of epileptic systems rather than on isolated molecular targets alone. Within a neural–glial instability framework, these approaches are valuable because they align closely with the idea that epilepsy is sustained by interacting disturbances across circuits, cell types, and time scales [229, 244, 245].

One important class of strategies involves neuromodulation. Approaches such as electrical stimulation, responsive stimulation, or related circuit-level interventions may help reduce seizure burden not only by interrupting abnormal activity, but by altering the network conditions that permit pathological synchronization and propagation [244, 246]. In selected cases, surgical resection or disconnection can also be understood as a network-level intervention, particularly when a dominant epileptogenic node or pathway can be identified and safely targeted [247, 248]. From the perspective of this review, these strategies are important because they reflect a shift from targeting isolated molecular mechanisms to regulating unstable network behavior more directly.

A second major component of precision therapy is the development and use of biomarkers. If epilepsy is biologically heterogeneous, then therapies directed at inhibition, glia, inflammation, calcium signaling, or circuit remodeling are unlikely to be equally effective across all patients [229, 249]. Electrophysiological, imaging-based, molecular, inflammatory, and other multimodal biomarkers may therefore be essential for identifying the dominant mechanisms operating in a given patient and for matching interventions to those mechanisms more precisely [229, 249]. This is especially relevant for translational progress, because it moves therapy away from uniform empiricism and toward mechanism-informed stratification.

Patient-specific models also offer a promising route toward more individualized intervention. Human tissue studies, stem cell-derived systems, organoids, and related personalized platforms may help identify patient-relevant cellular vulnerabilities, developmental mechanisms, drug responses, or network phenotypes that are not fully captured by generalized models [250, 251]. Although these approaches remain technically and translationally challenging, they are conceptually important because they allow the biology of epilepsy to be studied in forms that are closer to the patient’s own cellular context. This may become especially valuable for syndromes with strong genetic, developmental, or drug-resistant features.

More broadly, the future of epilepsy treatment may depend on systems-guided therapies that integrate multiple levels of information rather than focusing on a single pathway in isolation. In practice, this could mean combining pharmacological treatment with biomarker-guided anti-inflammatory strategies, glial modulation, calcium- or stress-directed interventions, neuromodulation, or circuit-targeted procedures depending on the dominant architecture of instability in a given case [229, 230]. Such a framework is well suited to epilepsy because the disease often reflects converging dysfunctions rather than a single lesion in one signaling pathway. Systems-guided therapy therefore represents not therapeutic complexity for its own sake, but a more biologically faithful response to the structure of the disorder.

Taken together, network-level and precision approaches extend the translational implications of this review beyond conventional seizure control. They emphasize that durable benefit may come from identifying and correcting the specific configurations of instability that sustain epileptic networks in different patients [229, 244, 245]. Within this framework, effective therapy is not defined only by immediate seizure suppression, but by whether it helps restore the conditions under which neural–glial systems can recover more stable function. The future of epilepsy therapy may therefore depend less on suppressing seizures uniformly and more on restoring the particular form of stability lost in each patient. These therapeutic strategies are summarized in Table 4 as a network-stabilization framework that links mechanistic insight to translational intervention in epilepsy.

The translational logic of restoring network stability across interacting neuronal and glial mechanisms is illustrated in Figure 3.